2. Academic Validation
  3. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis

Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis

  • Bioorg Med Chem Lett. 2018 Nov 1;28(20):3372-3375. doi: 10.1016/j.bmcl.2018.09.001.
Imadul Islam 1,  Shendong Yuan 2,  Christopher W West 2,  Marc Adler 3,  Ulrich Bothe 4,  Judi Bryant 2,  Zheng Chang 2,  Kieu Chu 5,  Kumar Emayan 2,  Giovanna Gualtieri 2,  Elena Ho 6,  David Light 7,  Cornell Mallari 6,  John Morser 8,  Gary Phillips 2,  Caralee Schaefer 6,  Drew Sukovich 5,  Marc Whitlow 3,  Deborah Chen 2,  Brad O Buckman 2
Affiliations

Affiliations

  • 1 Medical Core Facility and Research Platforms, King Abdullah International Medical Research Center/King Saud Bin, Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh 11426, Saudi Arabia; Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States. Electronic address: imadulislam@yahoo.com.
  • 2 Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States.
  • 3 Department of Biophysics, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States.
  • 4 Department of Medicinal Chemistry, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States; Research and Development Pharmaceutical, Bayer AG, 13342 Berlin, Germany.
  • 5 Department of Molecular Pharmacology, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States.
  • 6 Department of Animal Pharmacology, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States.
  • 7 Department of Antibody Technology, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States.
  • 8 Cardiovascular Department, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, United States.
PMID: 30201291 DOI: 10.1016/j.bmcl.2018.09.001
Abstract

We report here the design and synthesis of a novel series of benzylamines that are potent and selective inhibitors of uPA with promising oral availability in rat. Further evaluation of one representative (ZK824859) of the new structural class showed that this compound lowered clinical scores when dosed in either acute or chronic mouse EAE models, suggesting that uPA inhibitors of this type could be useful for the treatment of multiple sclerosis.

Keywords

Multiple sclerosis; Serine protease; Urokinase; uPA; uPA inhibitor.

Figures
Products